ArticleClinical and translational medicine2022

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.

Gehan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.